IBDEI1ZB ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1232,0)
 ;;=PREGNANCY-OTH COMP OF PUERPERIUM^11^115
 ;;^UTILITY(U,$J,358.4,1233,0)
 ;;=PREGNANCY-OTHER COMPLICATIONS^10^115
 ;;^UTILITY(U,$J,358.4,1234,0)
 ;;=PREGNANCY-OTHER CONDITIONS^12^115
 ;;^UTILITY(U,$J,358.4,1235,0)
 ;;=PREGNANCY-PROBLEMS W/ AMNIO/MEMBRANES^13^115
 ;;^UTILITY(U,$J,358.4,1236,0)
 ;;=PREGNANCY-PYREXIA^15^115
 ;;^UTILITY(U,$J,358.4,1237,0)
 ;;=PREGNANCY-V CODES^16^115
 ;;^UTILITY(U,$J,358.4,1238,0)
 ;;=PREGNANCY-VENOUS COMPLICATIONS^17^115
 ;;^UTILITY(U,$J,358.4,1239,0)
 ;;=PREGNANCY-VOMITING^18^115
 ;;^UTILITY(U,$J,358.4,1240,0)
 ;;=V CODES^19^115
 ;;^UTILITY(U,$J,358.4,1241,0)
 ;;=SPECIAL SERVICES^9^116
 ;;^UTILITY(U,$J,358.4,1242,0)
 ;;=CHEMO NURSE PROCEDURES^2^116
 ;;^UTILITY(U,$J,358.4,1243,0)
 ;;=INFUSION DRUGS^6^116
 ;;^UTILITY(U,$J,358.4,1244,0)
 ;;=BLOOD PRODUCTS^1^116
 ;;^UTILITY(U,$J,358.4,1245,0)
 ;;=DIAGNOSTIC PROCEDURES^3^116
 ;;^UTILITY(U,$J,358.4,1246,0)
 ;;=OTHER DRUGS^7^116
 ;;^UTILITY(U,$J,358.4,1247,0)
 ;;=IMMUNIZATION ADMINISTRATION^4^116
 ;;^UTILITY(U,$J,358.4,1248,0)
 ;;=IMMUNIZATIONS^5^116
 ;;^UTILITY(U,$J,358.4,1249,0)
 ;;=PROLONGED SERVICES^8^116
 ;;^UTILITY(U,$J,358.4,1250,0)
 ;;=NEW PATIENT^2^117
 ;;^UTILITY(U,$J,358.4,1251,0)
 ;;=ESTABLISHED PATIENT^1^117
 ;;^UTILITY(U,$J,358.4,1252,0)
 ;;=CONSULTATIONS^3^117
 ;;^UTILITY(U,$J,358.4,1253,0)
 ;;=ANEMIA^1^118
 ;;^UTILITY(U,$J,358.4,1254,0)
 ;;=COAGULATION DISORDERS^4^118
 ;;^UTILITY(U,$J,358.4,1255,0)
 ;;=MYELOID NEOPLASMS & DISORDERS^12^118
 ;;^UTILITY(U,$J,358.4,1256,0)
 ;;=LYMPHOID NEOPLASMS^9^118
 ;;^UTILITY(U,$J,358.4,1257,0)
 ;;=GI NEOPLASMS^7^118
 ;;^UTILITY(U,$J,358.4,1258,0)
 ;;=HEAD, NECK & LUNG NEOPLASMS^8^118
 ;;^UTILITY(U,$J,358.4,1259,0)
 ;;=MISC. NEOPLASMS^11^118
 ;;^UTILITY(U,$J,358.4,1260,0)
 ;;=METASTATIC SITES^10^118
 ;;^UTILITY(U,$J,358.4,1261,0)
 ;;=COUNSELING & SCREENING^5^118
 ;;^UTILITY(U,$J,358.4,1262,0)
 ;;=GENITOURINARY NEOPLASMS^6^118
 ;;^UTILITY(U,$J,358.4,1263,0)
 ;;=BREAST & GYN NEOPLASMS^3^118
 ;;^UTILITY(U,$J,358.4,1264,0)
 ;;=ARTIFICIAL OPENING STATUS^2^118
 ;;^UTILITY(U,$J,358.4,1265,0)
 ;;=PERSONAL HX OF CANCER^15^118
 ;;^UTILITY(U,$J,358.4,1266,0)
 ;;=NEOPLASMS OF UNCERTAIN BEHAVIOR^13^118
 ;;^UTILITY(U,$J,358.4,1267,0)
 ;;=NEOPLASMS OF UNSPECIFIED NATURE^14^118
 ;;^UTILITY(U,$J,358.4,1268,0)
 ;;=INJECTION/ASPIRATION^3^119
 ;;^UTILITY(U,$J,358.4,1269,0)
 ;;=FRACTURE DISLOCATION^2^119
 ;;^UTILITY(U,$J,358.4,1270,0)
 ;;=APPLICATION CASTS/STRAPPING^1^119
 ;;^UTILITY(U,$J,358.4,1271,0)
 ;;=OTHER/REMOVAL/REVISION^4^119
 ;;^UTILITY(U,$J,358.4,1272,0)
 ;;=SUPPLIES/SOFT GOODS^7^119
 ;;^UTILITY(U,$J,358.4,1273,0)
 ;;=SUPPLIES/DRUGS^6^119
 ;;^UTILITY(U,$J,358.4,1274,0)
 ;;=REPAIR/CLOSURE^5^119
 ;;^UTILITY(U,$J,358.4,1275,0)
 ;;=NEW PATIENT^2^120
 ;;^UTILITY(U,$J,358.4,1276,0)
 ;;=ESTABLISHED PATIENT^1^120
 ;;^UTILITY(U,$J,358.4,1277,0)
 ;;=CONSULTATIONS^3^120
 ;;^UTILITY(U,$J,358.4,1278,0)
 ;;=POST OP^4^120
 ;;^UTILITY(U,$J,358.4,1279,0)
 ;;=HAND/FINGER^8^121
 ;;^UTILITY(U,$J,358.4,1280,0)
 ;;=WRIST^20^121
 ;;^UTILITY(U,$J,358.4,1281,0)
 ;;=FOREARM^7^121
 ;;^UTILITY(U,$J,358.4,1282,0)
 ;;=ELBOW^4^121
 ;;^UTILITY(U,$J,358.4,1283,0)
 ;;=HUMERUS^9^121
 ;;^UTILITY(U,$J,358.4,1284,0)
 ;;=SHOULDER^16^121
 ;;^UTILITY(U,$J,358.4,1285,0)
 ;;=SPINE/GENERAL^17^121
 ;;^UTILITY(U,$J,358.4,1286,0)
 ;;=CERVICAL SPINE^3^121
 ;;^UTILITY(U,$J,358.4,1287,0)
 ;;=THORACIC^18^121
 ;;^UTILITY(U,$J,358.4,1288,0)
 ;;=LUMBAR SPINE^11^121
 ;;^UTILITY(U,$J,358.4,1289,0)
 ;;=SACRUM/COCCYX^15^121
 ;;^UTILITY(U,$J,358.4,1290,0)
 ;;=PELVIS/HIP^14^121
 ;;^UTILITY(U,$J,358.4,1291,0)
 ;;=FEMUR/THIGH^5^121
